TD Cowen upgraded Ascendis Pharma to Buy from Hold with a price target of $175, up from $156.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Data from Phase 2 ACcomplisH Trial of TransCon CNP in Children with Achondroplasia Presented at ICCHBH 2024
- Ascendis Pharma Updates Corporate Financial Strategy
- Ascendis Pharma to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
- Ascendis presents new data/results of Phase 1/2 IL-Believe Trial at ASCO
- Ascendis Pharma Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024